[ad_1]
Wall Street analysts take a more pessimistic view of CureVac as the stock collapses after the German biotech reported disappointing results from its last-stage trial of a Covid-19 vaccine on Wednesday.
In a note Thursday, Guggenheim analyst Seamus Fernandez wrote that he now estimates the fair value range for CureVac shares (stock ticker: CVAC) between $15 and $30 per share, down from his previous estimate of $90 to $110.
which – which…
.
[ad_2]
Picture Credit!